NASDAQ:PKBO Peak Bio (PKBO) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free PKBO Stock Alerts $0.0085 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0085▼$0.008550-Day Range$0.00▼$0.0452-Week Range$0.00▼$1.00VolumeN/AAverage Volume60 shsMarket Capitalization$192,355.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Get Peak Bio alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Peak Bio Stock (NASDAQ:PKBO)Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.Read More PKBO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PKBO Stock News HeadlinesApril 11, 2024 | msn.comOppenheimer starts Q32 Bio at outperform, cites lead assetMarch 6, 2024 | msn.comAkari Therapeutics enters merger deal with Peak BioApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 5, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with AkariMarch 5, 2024 | globenewswire.comAkari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) ToolkitFebruary 17, 2024 | benzinga.comPyramid Peak Foundation's Net WorthFebruary 7, 2024 | markets.businessinsider.comPeak Bio Raises Capital via Convertible Promissory NotesJanuary 4, 2024 | finance.yahoo.comPeak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA SplicingApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.December 12, 2023 | businessinsider.comWhen to watch the spectacular Geminid meteor shower this week. NASA says skies are ideal for viewing it.September 19, 2023 | finance.yahoo.comPeak Bio, Inc. Announces Filing of Provisional Patent Applications for PH-1, a Novel and Specific Immunomodulatory ADC payload platform targeting RNA splicingSeptember 14, 2023 | finance.yahoo.comInsider Buying: Hoyoung Huh Acquires 47,000 Shares of Peak Bio Inc (PKBO)August 31, 2023 | theglobeandmail.comBioPharma Uplists to OTCQBAugust 31, 2023 | benzinga.comPeak Bio, Inc. Announces Up-listing to OTCQB MarketAugust 31, 2023 | finance.yahoo.comPeak Bio, Inc., Announces Appointment of Michael Friedman to Board of DirectorsAugust 31, 2023 | finance.yahoo.comPeak Bio, Inc., Announces Appointment of Michael Friedman to Board of DirectorsAugust 31, 2023 | finance.yahoo.comPeak Bio, Inc. Announces Up-listing to OTCQB MarketAugust 24, 2023 | finance.yahoo.comPeak Bio, Inc. Announces Amendment and Continued Access to Equity Line of up to $100 Million USD via an Accelerated Common Stock Purchase Transaction with White Lion CapitalAugust 23, 2023 | finance.yahoo.comPeak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual MeetingAugust 10, 2023 | msn.comBio-Rad: A Cash Flow Returns On Investments AnalysisFebruary 25, 2023 | msn.com"I don't need a therapist because I have Talat Mahmood": A sneak peak into the legendary singer's biographyFebruary 20, 2023 | yahoo.comBioAro Unveils Its Targeted Cardiac Panel for Patients Facing the Risk of Heart Failure During the Peak of Heart MonthJanuary 28, 2023 | nypost.comFinding peak travel outfits with Alan CummingJanuary 9, 2023 | msn.comWhy Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day SessionNovember 25, 2022 | seekingalpha.comNewly public Peak Bio stock rallies 27% in wake of SPAC mergerNovember 25, 2022 | benzinga.comWhy Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day SessionNovember 4, 2022 | seekingalpha.comNewly public Peak Bio falls for second day following SPAC mergerSee More Headlines Receive PKBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Peak Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PKBO CUSIPN/A CIK1834645 Webpeak-bio.com Phone650-549-9103FaxN/AEmployees21Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$610,000.00 Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-0.02Miscellaneous Outstanding Shares22,630,000Free Float18,129,000Market Cap$192,355.00 OptionableNot Optionable Beta0.51 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Hoyoung Huh M.D. (Age 55)Ph.D., Executive Chairman (Leave of Absence) Comp: $1.67MDr. Stephen LaMond M.B.A. (Age 62)Pharm.D., PharmD MBA, Interim CEO, COO, Secretary & Director Comp: $499.17kDr. Satyajit Mitra Ph.D. (Age 50)Head of Oncology & Executive Director Comp: $317.22kMr. Timothy M. Cunningham CPA (Age 61)M.B.A., Acting Chief Financial Officer Ms. Moddy WongDirector of Human ResourcesMs. Divya PatelController & TreasurerMore ExecutivesKey CompetitorsIgnyte AcquisitionNASDAQ:IGNYCalithera BiosciencesNASDAQ:CALAPolarityTENASDAQ:PTEIQScopus BioPharmaNASDAQ:SCPSStatera BiopharmaNASDAQ:STABView All Competitors PKBO Stock Analysis - Frequently Asked Questions How have PKBO shares performed in 2024? Peak Bio's stock was trading at $0.1875 at the beginning of 2024. Since then, PKBO shares have decreased by 95.5% and is now trading at $0.0085. View the best growth stocks for 2024 here. How do I buy shares of Peak Bio? Shares of PKBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PKBO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Peak Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
